Alborz Investment Group

What Alborz Investment Group does

Alborz Investment Group (سرمایه گذاری البرز) is an Iranian publicly-listed pharmaceutical holding company headquartered in Tehran, originally founded in 1966 as Yekdel and renamed Alborz Investment Co. in 1974. It was the first investment company admitted to the Tehran Stock Exchange (TSETMC code 57944184894703821) and reports more than 70,000 shareholders. The group operates a vertically integrated pharmaceutical value chain across 10 wholly-owned operating subsidiaries spanning active pharmaceutical ingredient (API) manufacturing, finished drug formulation, import/trading, investment management, and nationwide distribution. Manufacturing subsidiaries include Alborz Bulk (APIs across steroids, cephalosporins, and general drugs; 333,000 kg annual capacity across four plants), Alborz Darou (the largest cardiovascular drug producer and fourth-largest pharmaceutical producer in Iran), Iran Darou (12 therapeutic categories), Sobhan Darou (second-largest neuropsychiatric drug producer), Tolid Darou (five production lines including sterile injectables), and Sobhan Oncology (first injectable anticancer drug manufacturer in the Middle East, second globally to commercialize nano-liposomal Doxorubicin). The group produces 750+ drug types across 12 therapeutic areas and holds over 14% of Iran's pharmaceutical market share.

The group's commercial model combines B2B/B2G sales to hospitals, pharmacies, and clinics across Iran with import/trading through KBC (the only TSE-listed pharmaceutical trading company, supplying vaccines to the Ministry of Health) and investment management through Etela Alborz Investment (53% five-year average portfolio return vs. 38% market average). Distribution is handled primarily by Pakhsh Alborz, Iran's largest pharmaceutical distributor with 27 distribution centers across the country, 200,000 sqm of land, 90,000 sqm of covered warehouses, and 13,000 billion IRR in recorded annual sales. Pakhsh Alborz holds exclusive licenses for controlled substances, narcotics, hemodialysis products, and subsidized infant formula, and serves 65 pharmaceutical companies plus 23 food and cosmetics companies. Group headcount stands at 3,200+ across subsidiaries, with the bulk concentrated in manufacturing (Sobhan Darou 374, Alborz Darou 380, Tolid Darou 310, Iran Darou 246, Sobhan Oncology 160) and distribution (Pakhsh Alborz 1,340). Pricing is regulated by Iran's Food and Drug Administration. The group has set a 10% export-share target by 2025 via dedicated export entities, marking its first material expansion outside Iran.

Name

Alborz Investment Group

Legal name

شرکت سرمایه گذاری البرز (سهامی عام) / Alborz Investment Co. (Public Joint Stock Company)

Website

https://alborzinvest.ir

Company type

Public

Founded year

1966

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Alborz Investment Group is an Iranian publicly-listed pharmaceutical holding company operating a vertically integrated value chain of 10 subsidiaries spanning API manufacturing, drug formulation, import/trading, and nationwide distribution. It holds 14%+ of Iran's pharma market, produces 750+ drug types across 12 therapeutic areas, and runs the country's largest distribution network with 27 centers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

Keywords

• Pharmaceutical manufacturing
• Drug distribution
• Active pharmaceutical ingredients
• Oncology drug production
• Pharmaceutical holding

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing: The group generates revenue primarily through manufacturing and sale of pharmaceutical products across its 10 subsidiary companies, producing over 750 drug types in 12 therapeutic areas including oncology, cardiovascular, neurology, and more.
2. Pharmaceutical Distribution: Pakhsh Alborz distributes pharmaceutical, food, hygiene, and medical equipment products nationwide through its 27 distribution centers, generating revenue through distribution fees and service charges. The company has recorded sales of 13,000 billion Rials.
3. Pharmaceutical Trading/Import: KBC Company generates revenue through importing and trading pharmaceutical products including vaccines, specialized medicines, and pharmaceutical commodities, distributing them through contracted distribution partners.
4. Capital Market Investments: Etela Alborz Investment manages the group's portfolio on the Tehran Stock Exchange, with a focus on pharmaceutical sector investments. The investment company holds stakes in listed pharmaceutical subsidiaries.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Alborz Investment Group is a publicly listed pharmaceutical investment holding company that operates a vertically integrated pharmaceutical value chain in Iran through 10-13 wholly-owned subsidiaries. The subsidiaries manufacture active pharmaceutical ingredients (Alborz Bulk), produce finished dosage form drugs across multiple therapeutic areas including oncology, cardiovascular, and neurology (Sobhan Oncology, Sobhan Darou, Alborz Darou, Iran Darou, Tolid Darou), operate Iran's largest nationwide pharmaceutical distribution network (Pakhsh Alborz with 27 distribution centers), import and trade pharmaceuticals and vaccines (KBC Company), and manage a specialized investment portfolio on the Tehran Stock Exchange (Etela Alborz Investment).

Product overview

Alborz Investment Group is a specialized pharmaceutical investment holding company operating a diversified portfolio of 10–13 subsidiary companies spanning the complete pharmaceutical value chain. The group's products and services are organized into three interconnected layers: (1) active pharmaceutical ingredient (API) manufacturing through Alborz Bulk (البرز بالک), (2) pharmaceutical formulation production across multiple sub-brands — Sobhan Darou (specializing in neuropsychiatric drugs), Alborz Darou (cardiovascular and injectable drugs, the 4th largest producer in Iran), Iran Darou (broad therapeutic portfolio), Tolid Darou (five production lines including injectables and steriles), and Sobhan Oncology (anti-cancer injectable drugs, the first and most advanced in the Middle East using nano-technology) — and (3) pharmaceutical distribution and investment services through Pakhsh Alborz (the largest national distributor with 27 centers), KBC Company (specialized trading and import), and Etela Alborz Investment (investment portfolio management). The group produces over 750 types of drugs across 12 therapeutic areas, holding 14% of Iran's pharmaceutical market share and serving as the second-largest pharmaceutical holding company in the country.

Differentiator

Problem solved

Functional benefit

Products and services

• Alborz Darou (البرز دارو) Pharmaceutical manufacturer and importer that is the largest producer of cardiovascular drugs in Iran and the country's fourth-largest pharmaceutical producer overall. Supplies cardiovascular and injectable pharmaceutical products to healthcare institutions and pharmacies throughout Iran. Holds ISO 9001, ISO 14001, ISO 17025, and IMS certifications and has received international recognition from the European Union for product quality and brand.
• Sobhan Darou (سبحان دارو) Manufacturer of human pharmaceuticals, cosmetics, and health products; ranks 2nd nationally in neuropsychiatric drug production volume and 9th in national pharmaceutical sales. The plant covers 24,287 sqm with 5,000+ sqm of built area and holds ISO 9001:2008, ISO 14001:2004, and GMP certifications. Supplies CNS/psychiatric, cardiovascular, and gastrointestinal medicines to Iranian healthcare institutions.
• Iran Darou (ایران دارو) Long-established pharmaceutical company producing products across 12 therapeutic categories including cardiovascular, dermatological, neurological, and nutritional supplements. Holds ISO 9001, ISO 14001 certifications and Green Industry recognition from the Iran Environmental Organization. Workforce of approximately 246 employees distributed across production (86), warehouses and production support (92), and administrative functions (68).
• Tolid Darou (داروسازی تولید دارو) One of Iran's largest and oldest pharmaceutical manufacturers, producing 135 pharmaceutical items across five production lines including liquids, semi-solids, solids, injectables, and sterile products. Holds triple ISO certifications (ISO 9001:2008, ISO 14001:2004, and ISO 18001:2007) covering quality, environment, and occupational health and safety.
• Sobhan Oncology (سبحان آنکولوژی) First and most advanced injectable anticancer drug manufacturer in the Middle East. Uses proprietary nanotechnology to produce Doxorubicin nanoliposomal; the second company globally after the United States to bring this product to market. Holds GMP certification for solid and injectable production lines, ISO 9001 and ISO 14001 certifications, and has received International Quality Excellence Award from BID (Business Initiative Directions).
• Alborz Bulk (البرز بالک) Active pharmaceutical ingredient (API) manufacturer with specialized production lines for steroids, cephalosporins, and general APIs across four production plants with combined capacity of 333,000 kg per year. Holds ISO 9001:2008 certification and GMP certification for its C1, C2, and C3 production facilities.
• KBC Company (کی بی سی) Pharmaceutical trading and import company specializing in imported pharmaceuticals and vaccines; sole pharmaceutical trading company listed on the Tehran Stock Exchange. Major supplier of vaccines and specialized pharmaceuticals to the Iranian Ministry of Health. Holds ISO 9001:2008 certification from TUV NORD Germany and is ranked among Iran's top 500 companies (IMI100).
• Pakhsh Alborz (پخش البرز) Largest pharmaceutical distribution company in Iran, operating 27 distribution centers nationwide covering Tehran (East, West, specialized, corporate, wholesale), Mashhad, Isfahan, Shiraz, Ahvaz, Tabriz, Hamedan, Yazd, Urmia, Kermanshah, Kerman, Rasht, Zahedan, Arak, Babol, Gorgan, Sanandaj, Bandar Abbas, Karaj, Qazvin, Qom, Ardabil, Zanjan, and Ganavabad. Distributes products for 65 pharmaceutical companies and 23 food and cosmetics companies. Holds exclusive nationwide distribution licenses for controlled substances, narcotics, hemodialysis products, and subsidized infant formula, plus cold-chain distribution license. Operates ERP systems, BI platforms, SIPA mobile ordering, and SALPA real-time tracking systems across 90,000 sqm of covered storage. First pharmaceutical distribution company listed on the Tehran Stock Exchange and member of the 'thousand billion Toman' revenue club.
• Etela Alborz Investment (سرمایه گذاری اعتلاء البرز) Specialized investment arm managing a non-executive portfolio focused on the pharmaceutical industry, with a 53% average portfolio return over 5 years compared to a 38% average annual market return. Holds stakes in listed pharmaceutical subsidiaries and serves the group's 70,000+ shareholders.

Quantifiable outcome

• 14%+ market share of Iran's pharmaceutical market
• +4 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators11 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Cipla: Large Indian generic pharmaceutical manufacturer with global distribution and broad therapeutic-area portfolio. Comparable in vertical API-to-finished-dose manufacturing, generics scale, and emerging-market roots.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing generics, branded, and consumer health products. Compares as a regional integrated pharma manufacturer operating across MENA with comparable scale and therapeutic breadth.
• Aspen Pharmacare: South African pharmaceutical holding company with vertical integration across specialty, generic, consumer health, and distribution. Comparable in emerging-market pharma holding structure and supply-chain depth.
• SPIMACO: Saudi Pharmaceutical Industries & Medical Appliances Corporation — integrated pharmaceutical manufacturer and distributor operating across MENA with vertically integrated production. Structurally comparable to Alborz as a regional pharma holding with manufacturing-distribution-tied subsidiaries.
• Krka: Slovenian pharmaceutical company with strong vertical integration in generic-drug manufacturing and own-API production. Comparable as an integrated pharma group with developed distribution and broad therapeutic portfolio.
• Hikma Pharmaceuticals: Jordan-headquartered specialty and generic pharmaceutical company with global manufacturing and distribution. Comparable to Alborz in MENA roots, vertical integration across API-to-distribution, and broad therapeutic-category portfolio.
• Dr. Reddy's Laboratories: Indian integrated pharmaceutical company with API and finished-dose manufacturing across multiple therapeutic categories and global commercial reach. Comparable in vertical integration, generics emphasis, and broader specialty exposure.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with broad generic and specialty portfolio and global distribution footprint. Comparable in scale and vertical integration, though substantially larger globally.

Regional players

• Eva Pharma: Egyptian pharmaceutical company with manufacturing and distribution across the MENA region. Comparable as a regional pharma player with portfolio breadth and finished-dose manufacturing capacity.
• EIPICO: Egyptian pharmaceutical manufacturer with API and finished-dose production across multiple therapeutic areas. Comparable as a regional pharma manufacturer similar in scale and product breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alborz-investment-group

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alborz Investment Group